Biotransformation of taxoids by human cytochromes P450: Structure-activity relationship

Bulletin du Cancer

Volumn 84, Issue 2, 1997, Pages 125-133

  Monsarrat, Bernard ^a   Royer, Isabelle ^a   Wright, Michel ^a   Cresteil, Thierry ^b  

^a Lab Pharmacologie Toxicologie F   (France)

^b INSERM   (France)

Author keywords

CYP2C8; CYP3A4; docetaxel; human liver microsomes; induction; inhibition; interactions; metabolism; paclitaxel

Indexed keywords

BARBITURIC ACID DERIVATIVE; CIMETIDINE; CISPLATIN; CYTOCHROME P450; DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; DRUG METABOLITE; KETOCONAZOLE; PACLITAXEL; PACLITAXEL DERIVATIVE; RANITIDINE; VERAPAMIL; VINBLASTINE; VINCRISTINE;

ARTICLE; BIOTRANSFORMATION; DRUG METABOLISM; HUMAN; HUMAN TISSUE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; ISOENZYMES; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; PACLITAXEL; RATS; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP; TAXOIDS;

EID: 0030957370     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Anderson CD, Wang J, Kumar GN, McMillan JM, Walle UK, Walle T. Dexamethasone induction of taxol metabolism in the rat. Drug Metab Dispos 1995; 23: 1286-90.
2. ® (RP 56976, NSC 628503) a taxol analogue. Cancer Res 1991; 51: 4845-52.
3. Bourzat JM, Lavelle F, Commercon A. Synthesis and biological activity of para-substituted 3′-phenyl docetaxel analogs. Bioorg Med Chem Lett 1995; 5: 809-14.
4. ™ (Docetaxel). Cancer Surveys 1993, 17; 305-13.
5. Burke MD, Thompson S, Elcombe CR, Halpert J, Haaparanta T, Mayer RT. Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P450. Biochem Pharmacol 1985; 34: 3337-45.
6. Chen SH, Kant J, Mamber SW, Roth GP, Wei JM, Marshall D, Vyas DM, Farina V. Taxol structure-activity relationships: synthesis and biological evaluation of taxol analogs modified at C7. Bioorg Med Chem Lett 1994; 4: 2223-8.
7. Chung LWK, Chao H. Neonatal imprinting and hepatic cytochrome P450. Comparison of testosterone hydroxylation in a reconstituted system between neonatally imprinted and nonimprinted rats. Mol Pharmacol 1980; 18: 543-9.
8. Cresteil T, Flinois JP, Pfister A, Leroux JP. Effect of microsomal preparations and induction on cytochrome P450-dependent monooxygenases in fetal and neonatal rat liver. Biochem Pharmacol 1979; 28: 2057-63.
9. Cresteil T, Beaune P, Kremers P, Celier C, Guengerich FP, Leroux JP. Immunoquantification of epoxide hydrolase and cytochrome P-450 isoenzymes in fetal and adult human liver microsomes. Eur J Biochem 1985; 151: 345-50.
10. Cresteil T, Monsarrat B, Alvinerie P, Treluyer JM, Vieira I, Wright M. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 1994; 54: 386-92.
11. De Waziers I, Cugnenc PH, Yang CS, Leroux JP, Beaune P. Cytochrome P450 isoenzymes epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther 1990; 253: 387-94.
12. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Locatelli A, Bonadonna G, Egorin MJ. Non linear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995; 13: 180-90.
13. Gonzalez FJ. The molecular biology of cytochrome P450s. Pharmacol Rev 1989; 40: 243-88.
14. Greim H. Synthesesteigerung und abbauhemmung bei der vermchrung der mikrosomalen cytochrome P450 und b5 durch phenobarbital. Arch Pharmacol 1970; 266: 261-75.
15. Guenard D, Gueritte-Voegelein F, Dubois J, Potier P. Structure-activity relationships of taxol and taxotere analogues. J Natl Cancer Inst 1993; 15: 79-82.
16. Gueritte-Voegelein F, Senilh V, David B, Guenard D, Potier P. Chemical studies of 10-deacetylbaccatin III. Hemisynthesis of taxol derivatives. Tetrahedron 1986; 42: 4451-60.
17. Gueritte-Voegelein F, Guenard D, Lavelle F, Le Goff MT, Mangatal L, Potier P. Relationship between the structure of taxol analogues and their antimititic activity. J Med Chem 1991; 34: 992-8.
18. Harris JW, Katki A, Anderson LW, Chmurny GN, Paukstelis JV, Collins JM. Isolation structural determination and biological activity of 6α-hydroxytaxol the principal human metabolite of taxol. J Med Chem 1994a; 37: 706-9.
19. Harris JW, Rahman A, Kim BR, Guengerich FP, Collins JM. Metabolism of taxol by human hepatic microsomes and liver slices: participotion of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 1994b; 54: 4026-35.
20. Haseman CA, Kurumbail RG, Boddupalli SS, Peterson JA, Deisenhofer J. Structure and function of cytochromes P450: a comparative analysis of three crystal structure. Structure 1995; 2: 41-62.
21. Ireland CM, Strickland D, Pittman SM. Tubulin alterations in taxol-induced apoptosis parallel those observed with other drugs. Biochem Pharmacol 1995; 49: 1491-9.
22. Kiffel L, Celier C, Leroux JP. Purification and characterization of P450 isozyme isolated from liver of rats pretreated with clofibrate. Biochem Biophys Res Commun 1988; 156: 282-9.
23. 3H-taxol in the Sprague-Dawley rat. Drug Metab Dispos 1994; 22: 254-8.
24. Klotz U, Arvela P, Pasanen M, Kroemer H, Pelkonen O. Comparative effects of H2-receptor antagonists on drug metabolism in vitro and in vivo. Pharmac Ther 1987; 3: 157-61.
25. Knodell RG, Hall SD, Wilkinson GR and Guengerich FP. Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. J Pharmacol Exp Ther 1987; 241: 1112-9.
26. Knodell RG, Browne DG, Gwozdz GP, Brian WR, Guengerich FP. Differential inhibition of individual human liver cytochromes P450 by cimetidine. Gastroenterology 1991; 101: 1680-91.
27. Komori M, NishioK, Kitada M, Shiramatsu K, Muroya K, Soma M, Nagashima K, Kamataki T. Fetus-specific expression of a form of cytochrome P450 in human livers. Biochemistry 1990; 29: 4430-3.
28. Kroemer HK, Echizen H, Heidemann H, Eichelbaum M. Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects. J Pharmacol Exp Ther 1992; 260: 1052-7.
29. Kumar GN, Oatis JE, Thornburg KR, Heldrich FJ, Hazard ES, Walle T. 6α-hydroxytaxol: isolation and identification of the major metabolite of taxol in human liver microsomes. Drug Metab Dispos 1994a; 22: 177-9.
30. Kumar GN, Walle UK, Walle T. Cytochrome P450 3A-mediated human liver microsomal taxol 6α-hydroxylation. J Pharmacol Exp Ther 1994b; 268: 1160-5.
31. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 1970; 227: 680-5.
32. Lataste H, Senilh V, Wright M, Guenard D, Potier P. Relationship between the structures of taxol and baccatine III and their in vitro action on the disassembly of mammalian brain and Physarum amoebal microtubules. Proc Natl Acad Sci USA 1984; 81: 4090-4.
33. LeProvost E, Cresteil T, Columelli S, Leroux JP. Immunological and enzymatic comparison of hepatic cytochrome P450 fractions from phenobarbital-, 3-methylcholanthrene-, β-naphthoflavone- and 2,3,7,8-tetrachlorodibenzo-p-dioxin-treated rots. Biochem Pharmacol 1983; 32: 1673-82.
34. Lowry OH, Rosebrough MJ, Farr AL, Randall RJ. Protein measurement with the Folin reagent. J Biol Chem 1951; 193: 265-75.
35. ®) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 1996; 56: 1296-302.
36. ®). Tetrahedron Lett 1994; 35: 3715-8.
37. Monsarrat B, Mariel E, Cros S, Gares M, Guenard D, Gueritte-Voegelein F, Wright M. Taxol metabolism. Isolation and characterization of three major metabolites of taxol in rat bile. Drug Metab Dispos 1990; 18: 895-901.
38. Monsarrat B, Alvinerie P, Wright M, Dubois J, Gueritte-Voegelein F, Guenard D, Donehower RC, Rowinsky EK. Hepatic metabolism and biliary clearance of taxol in rats and human. J Natl Cancer Inst Monogr 1993; 15: 39-46.
39. Nelson D, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, Gonzalez FJ, Coon MJ, Gunsalus IC, Gotoh O, Okuda K, Nebert DW. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes and nomenclature. DNA and Cell Biol 1993; 12: 1-51.
40. Peter R, Bocker R, Beaune P, Iwasaki M, Guengerich FP, Yang CS. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P450IIE1. Chem Res Toxicol 1990; 3: 566-73.
41. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW. Selective biotransformation of laxol to 6α-hydroxylaxol by human cytochrome P450 2C8. Cancer Res 1994; 54: 5543-6.
42. Reilly PEB, Thompson DA, Mason SR, Hooper WD. Cytochrome P450IIIA enzymes in rat liver microsomes. Involvement in C3-hydroxylation of diazepam and nordazepam but not N-dealkylation of diazepam and temazepam. Mol Pharmacol 1990; 37: 767-74.
43. Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): a semi-synthetic analog of taxol. J Natl Cancer Inst 1991; 83: 288-91.
44. Rowinsky EK, Donehower RC. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther 1991; 52: 35-84.
45. Rowinsky EK, Ross C, Donehower MD. Paclitaxel. N Engl J Med 1995; 332: 1004-14.
46. Royer I, Alvinerie P, Armand JP, Ho LK, Wright M, Monsarrat B. Paclitaxel metabolites in human plasma and urine: identification of 6α-hydroxytaxol, 7-epitaxol and taxol hydrolysis products using liquid chromatography/atmospheric-pressure chemical ionization mass spectrometry. Rapid Commun Mass Spectrom 1995; 9: 495-502.
47. Royer I, Monsarrat B, Sonnier M, Wright M, Cresteil T. Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 1996; 56: 58-65.
48. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 22: 665-7.
49. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci (USA) 1980; 77: 1561-5.
50. Sonnichsen DS, Liu Q, Schuetz EG, Pappo A, Rolling MV. Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 1995; 275: 566-75.
51. Sparreboom A, Huizing MT, Boesen JJB, Nooijen WJ, Van Tellingen O, Beijnen JH. Isolation, purification and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces. Cancer Chemother Pharmacol 1995; 36: 299-304.
52. Swindell CS, Heerding JM, Krauss NE. Characterization of the taxol structure-activity profile for the locus at the A-ring side chain. Bioorg Med Chem Lett 1994; 4: 1531-6.
53. Treluyer JM, Jacqz-Aigrain E, Alvarez F, Cresteil T. Expression of CYP2D6 in the developing human liver. Eur J Biochem 1991; 202: 583-8.
54. Vuilhorgne M, Gaillard C, Sanderink GJ, Royer I, Monsarrat B, Dubois J, Wright M. Metabolism of taxoid drugs. In: Chen T, Ojimal, eds. Taxane anticancer agents. ACS Symposium, 1995; 98-110.
55. Walle T, Walle UK, Kumar GN, Bhalla KN. Taxol metabolism and disposition in cancer patients. Drug Metab Dispos 1995; 23: 506-12.
56. Wang P, Beaune P, Kaminsky LS, Dannan GA, Kadlubar FF, Larrey D, Guengerich FP. Purification and characterization of six cytochrome P450 isozymes from human liver microsomes. Biochemistry 1983; 22: 5375-83.
57. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971; 93: 2325-7.
58. Wright M, Monsarrat B, Royer I, Rowinsky EK, Donehower RC, Cresteil T, Guenard D. Metabolism and pharmacology of taxoids. In: Farina V, ed. Chemistry and pharmacology of taxol and its derivatives. Elsevier, 1995; 131-64.
59. Zhou-Pan XR, Sérée E, Zhou XJ, Placidi M, Maurel P, Barra Y, Rahmani R. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 1993; 53: 5121-6.